Project Grant R01DA065625
- The National Institute on Drug Abuse awarded Arizona State University $193,958 on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a mixed-methods, community-engaged study examining the role of family and household members in reducing opioid overdose deaths. The project investigates household and family-level risk and protective factors associated with opioid overdose mortality, with particular focus on Hispanic populations underrepresented in overdose...
- The National Institute on Drug Abuse awarded Arizona State University $684,625 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the association between environmental heat and drug overdose-related risks among persons who use drugs in Phoenix, Arizona. The research employs a mixed-methods approach integrating big data analytics of Arizona Medicaid and hospital discharge data on drug-related emergency department visits and death certificate data on...
- The National Institute on Drug Abuse awarded the Regents of the University of Minnesota $423,500 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the neuropharmacology of xylazine and fentanyl interactions. The recipient will characterize the pharmacological mechanisms of xylazine alone and in combination with fentanyl using preclinical models of analgesia, sedation, opioid tolerance, opioid withdrawal, and opioid self-administration in mice. The...
- The National Institute on Drug Abuse awarded Arizona State University $691,107 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate predictors and outcomes of simultaneous cannabis and alcohol use in daily life. The research will recruit 300 emerging adults who engage in regular simultaneous use and conduct an ecological momentary assessment study with two 28-day data collection bursts at baseline and one-year follow-up. Participants will complete...
- The National Institute on Drug Abuse awarded Arizona State University $314,000 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct secondary data analysis applying mediation mixture modeling and machine learning to identify heterogeneous risk pathways leading to youth substance use initiation. The project uses the Adolescent Brain Cognitive Development (ABCD) Study, a national longitudinal dataset tracking youths' behavioral health, to examine...
- The National Institute on Drug Abuse awarded Thomas Jefferson University $693,000 on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on xylazine exposure among pregnant women who use opioids and to generate evidence-based approaches to treatment for this population. The research addresses the rapid spread of xylazine across the United States, with xylazine-positive overdoses increasing over 1,000 percent in the South and 750 percent in...
- The National Institute on Drug Abuse awarded the University of Pittsburgh $434,005 on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate xylazine's mechanisms of action on human cell receptors and identify natural product compounds that can reverse xylazine-induced damage. The research addresses a critical gap in understanding xylazine's pharmacological effects beyond its known action on alpha-2 adrenergic receptors. Current FDA-approved medications,...
- The National Institute on Drug Abuse awarded New York University $103,607 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct dissertation research on polysubstance use patterns and their associations with methadone maintenance treatment receipt and discontinuation among people who use drugs in New York State. The research uses a mixed-methods approach guided by the Social Ecological Model to identify latent polysubstance use patterns through urine...
- The National Institute on Drug Abuse awarded Arizona State University $730,989 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and pilot-test a community-developed parenting intervention program designed to prevent substance use disorder among children with incarcerated parents. The funded work adapts evidence-based parenting program components to address the specific circumstances of caregivers raising children with incarcerated parents (CIP), a...
- The National Institutes of Health Office of the Director awarded the University of North Carolina at Chapel Hill $908,804 on August 15, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate the effects of acute fentanyl and xylazine exposure on neural respiratory centers. The research examines how acute exposure to ultra-potent synthetic opioids and drug supply adulterants—fentanyl, xylazine, and dexmedetomidine—affect respiration and behavior through adaptations in the...
The National Institute on Drug Abuse awarded Arizona State University $1,546,664 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a four-year study characterizing xylazine-adulterated illicitly manufactured fentanyl use and xylazine test strip acceptance in the southwestern United States. The research integrates mixed-methods data collection on xylazine-related knowledge, experiences, and risks with urine toxicology analyses using onsite and laboratory-based liquid chromatography methods to assess xylazine and other drug exposures. The study applies a social-ecological model examining individual, interpersonal, communal, and societal factors of risk. Work is performed in the Phoenix Metro Area, Arizona, a region along active drug trafficking corridors. The project builds on an interdisciplinary collaboration among researchers at Arizona State University, Valleywise Health, and the Montgomery County Coroner's Office Toxicology Lab, with guidance from a community advisory board of key stakeholders in opioid-related intervention and policy development. The performance period runs through June 30, 2030, with place of performance in Tempe, Arizona.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 8/20/26 | ||
| Not listed | $773.3k | 8/10/26 |